1 / 6

Total cholesterol reduction induced by atorvastatin 10 mg vs. placebo in the ASCOT Study

Total cholesterol reduction induced by atorvastatin 10 mg vs. placebo in the ASCOT Study. Trygve B. Tjugen, et al. Arch Med Sci 2007;3:S97-S101. LDL cholesterol reduction induced by atorvastatin 10 mg vs. placebo in the ASCOT Study. Trygve B. Tjugen, et al. Arch Med Sci 2007;3:S97-S101.

yetty
Download Presentation

Total cholesterol reduction induced by atorvastatin 10 mg vs. placebo in the ASCOT Study

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Total cholesterol reduction induced by atorvastatin 10 mg vs. placebo in the ASCOT Study Trygve B. Tjugen, et al. Arch Med Sci 2007;3:S97-S101

  2. LDL cholesterol reduction induced by atorvastatin 10 mg vs. placebo in the ASCOT Study Trygve B. Tjugen, et al. Arch Med Sci 2007;3:S97-S101

  3. Kaplan-Meier curves showing 36% reduction in the primary endpoint of myocardial infarction or fatal coronary heart disease of treatment with atorvastatin 10 mg vs. placebo Trygve B. Tjugen, et al. Arch Med Sci 2007;3:S97-S101

  4. Point estimates and confidence intervals regarding atorvastatin vs. placebo for all pre-specified endpoints in the lipid-lowering arm in the ASCOT Study Trygve B. Tjugen, et al. Arch Med Sci 2007;3:S97-S101

  5. Interaction between lipid-lowering treatment and blood pressure lowering treatment in the ASCOT Study: the interaction was statistically significant for the primary endpoint but not for the secondary endpoints stroke and all cardiovascular events and procedures Trygve B. Tjugen, et al. Arch Med Sci 2007;3:S97-S101

  6. Summary of ESH-ESC 2007 hypertension guidelines and ESC-EASD 2007 guidelines on diabetes and cardiovascular disease: position statement regarding treatment with lipid-lowering agents Trygve B. Tjugen, et al. Arch Med Sci 2007;3:S97-S101

More Related